Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

250.92

+2.10 (0.84%)

as of Jul 21, 2026, 8:03:09 pm Market Open.

697 watching

Investor Insights

Jul 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown strong performance in the pharmaceutical sector, particularly after spinning off its orthopedics division. Despite challenges in the cardio business and ongoing talcum-cancer lawsuits, expert opinions are largely optimistic about the company's future prospects. The current focus on high-margin areas like medical devices and pharmaceuticals, combined with a strong drug pipeline, positions JNJ for growth. Although the stock may experience fluctuations around earnings reports, it is generally viewed as a buy during dips. Overall, experts suggest that JNJ remains a sound investment, particularly for those interested in dividend growth and potential additional upside.

Consensus

Buy

Valuation

Fair Value

Similar

PAST TOP PICK

(A Top Pick Jan 29/09. Up 10.8%.) Not just pharmaceuticals, but a consumer's product company as well. Still likes. Great balance sheet and pays nice dividends.

TOP PICK

Cheap at 14X price to earnings. Gone through a little struggle in the last couple of years because of generic competition but that is basically at an end now and has a pipeline of new drugs that will not be subject to this. Well diversified. Over 3% dividend yield.

PAST TOP PICK

(A Top Pick Dec 22/08. Up 12.92%.)

BUY

Great holding. Gives you a piece of pharma, consumer goods and medical devices. 3.2% dividend. Trades at a reasonable multiple.

DON'T BUY

Great leadership name. Trading at around 12X forward earnings. Healthcare stocks tend not to do well when the market starts moving up. Quarterly estimates are being revised downwards. 3.25% dividend. Would prefer Pfizer (PFE-N).

PAST TOP PICK

(A Top Pick Oct 23/08. No change.) Still likes. Not just a pharmaceutical company but also consumer and medical devices businesses. Great balance sheet. 3%+ dividend. Historically has done a great job of growing its equity 10%-15%. Great core holding.

WAIT

(Market Call Minute.) Probably not a Buy for the next 3 or 4 months but longer-term it would be a buy.

PAST TOP PICK

(A Top Pick Sept 3/08. Down 15%.) Made a V base. 200-day moving average around $55. Would love to buy if it broke into new highs. Anything above $62-$63 would be confirmation of the beginning of a new leg.

Wealthica Track your Stocks in your Watch List

BUY

Household brand company with a tremendous franchise. Solid balance sheet and solid dividend. No matter what happens, it is not going to hurt you too badly. Be aware that on dividends outside Canada, you pay a lot more tax.

BUY ON WEAKNESS

Probably one of the best US pharmaceuticals. Also have consumer products. Steady earnings and dividend growth for over 20 years. The only risk is the currency effect by investing in a US company. Would like it at $57-$58.

TOP PICK

Healthcare space so is reasonably defensive. Well diversified including consumer products, prescription drugs and medical devices. Fantastic balance sheet management. About a 4% yield. History of increasing dividends.

PAST TOP PICK

(A Top Pick July 3/09. Up 7.31%.) Likes the diverse products in their pharmaceutical and medical devices as well as their consumer products area. Still a Buy.

TOP PICK

Sector most out of favour right now is healthcare. This is one of the most respected companies in the world with a very strong balance sheet. A leader in all its businesses. Wonderful consumer business. Very cheap with a 14 multiple.

BUY

Consumer discretionary and pharmaceuticals. A premier in its class. It does well when the US$ depreciates because of all their sales outside of the country. Good defensive play. Very good free cash flow. 3.2% yield.

PAST TOP PICK

(A Top Pick Aug 5/08. Down 12.21%.)

Showing 466 to 480 of 628 entries

Most Recent Experts

Julien Nono-Womdim

Goodreid Investment Council

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)